Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.


Journal Scan / Research · March 17, 2021

Safety and Efficacy of First-Line Dacomitinib in EGFR Mutation–Positive NSCLC

Lung Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

Lung Cancer
Safety and Efficacy of First-Line Dacomitinib in Asian Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: Results From a Randomized, Open-Label, Phase 3 Trial (ARCHER 1050)
Lung Cancer 2021 Feb 23;[EPub Ahead of Print], Y Cheng, TS Mok, X Zhou, et al

Further Reading